The non-WNT/non-SHH (Grp3/Grp4) medulloblastomas (MBs) include eight second-generation subgroups (SGS; I–VIII) each with distinct molecular and clinical characteristics. This evidence concerns the gene RASGRP3 and medulloblastoma.